1. Synagis® (paliwizumab) Charakterystyka Produktu Leczniczego
2. Goldstein M, Phillips R, DeVincenzo JP, et al. National Perinatal Association 2018 Respiratory Syncytial Virus (RSV) Prevention Clinical Practice Guideline: an evidence-based interdisciplinary collaboration. Neonatology Today. 2017;12:1-27
3. Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother. 2017;13(9):2138-2149. doi:10.1080/21645515.2017.1337614
4. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med. 2002;96(suppl B):S31-S35. doi:10.1053/rmed.2002.1298
5. Collins PL, Graham BS. Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol. 2008;82(5):2040-2055. doi:10.1128/JVI.01625-07
6. National Foundation for Infectious Diseases. Respiratory Syncytial Virus in Older Adults: A Hidden Annual Epidemic. Published September 2016. Accessed June 29, 2020. https://www.nfid.org/wp-content/uploads/2019/08/rsv-report.pdf
7. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev. 1999;12(2):298-309.
8. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occup Med (Lond). 2007;57(8):552-556. doi:10.1093/occmed/kqm110
9. Subramanian KN, Weisman LE, Rhodes T, et al; MEDI-493 Study Group. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr Infect Dis J. 1998;17(2):110-115. doi:10.1097/00006454-199802000-00006